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Available online 3 February 2016A better molecular understanding of gastrointestinal cancers arising either from the stomach, the pancreas, the
intestine, or the liver has led to the identiﬁcation of a variety of potential new molecular therapeutic targets.
However, inmost cases surgery remains the only curative option. The intratumoral cellular heterogeneity of can-
cer stem cells, bulk tumor cells, and stromal cells further limits straightforward targeting approaches. Accumulat-
ing evidence reveals an intimate link between embryonic development, stem cells, and cancer formation. In line,
a growingnumber of oncofetal proteins are found toplay common roleswithin these processes. Cancer stemcells
share features with true stem cells by having the capacity to self-renew in a de-differentiated state, to generate
heterogeneous types of differentiated progeny, and to give rise to the bulk tumor. Further, various studies iden-
tiﬁed genes in cancer stem cells, whichwere previously shown to regulate the pluripotency circuitry, particularly
the so-called “Yamanaka-Factors” (OCT4, KLF4, SOX2, and c-MYC). However, the true stemness potential of can-
cer stem cells and the role and expression pattern of such pluripotency genes in various tumor cell types remain
to be explored. Here, we summarize recent ﬁndings and discuss the potential mechanisms involved, and link
them to clinical signiﬁcance with a particular focus on gastrointestinal cancers.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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1.1. The “Yamanaka-Factors”
Stem cells are not only characterized by unlimited self-renewal, in
fact, they also have the capacity to differentiate into virtually all tissuethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cells using four distinct factors, thereby generating induced pluripotent
stem cells (iPSCs) from terminally differentiated ﬁbroblasts. IPSCs
can be established by the overexpression of four key transcription fac-
tors: OCT4, SOX2, KLF4, and c-MYC (OSKM) (Takahashi et al., 2007;
Takahashi and Yamanaka, 2006; Maherali et al., 2007). Reprogramming
of any somatic cell type can be achieved by initiating several synergistic
processes. In the process of reprogramming, induced pluripotency
elicits several transcriptional waves driven by c-MYC/KLF4 and OCT4/
SOX2/KLF4. The expression levels of distinct pluripotency genes
(alkaline phosphatase (AP), stage speciﬁc embryonic antigen (SSEA),
Nanog and OCT4) increase step-wise (Brambrink et al., 2008),
and upon achieving stable pluripotency levels, their DNA methylation
patterns are changed (Polo et al., 2012). Nonetheless, the exact
mechanisms of reprogramming still remain unclear. Obviously, the
reprogramming factors reactivate an endogenous pluripotency circuitry
by re-inducing the cells' capacity for unlimited growth without
inducting genetic alterations, as it is frequently observed in cancer
(Polo et al., 2012; Rais et al., 2013). It has been demonstrated that abbre-
viated (a slightly modiﬁed?) reprogramming factor expression pattern
results in dysplasia and tumor formation in vivo (Ohnishi et al., 2014),
thus suggesting that OSKM has an impact on epigenetic changes that
are substantially involved in the regulation of cell growth and tumori-
genesis. This observation is corroborated by the fact that iPSCs form
teratomas upon implantation in vivo (Magnuson et al., 1982). Of note,
human iPSCs develop teratoma more efﬁciently and faster than
human embryonic stem cells (ESCs) (Gutierrez-Aranda et al., 2010;
Avior et al., 2015).
1.2. Overexpression of OSKM leads to dysplasia and tumorigenesis in vivo
Several studies have assigned the OSKM factors to tumorigenesis.
Abad et al. were the ﬁrst to successfully reprogram in vivo by transiently
inducing OSKM, resulting in teratoma formation, and detection of fully
reprogrammed cells in various tissue types. Notably, the presence of
the niche in vivo even allowed superior reprogramming to the totipo-
tent state. However, this work is lacking any description regarding
non-teratoma tumor formation (Abad et al., 2013). Intriguingly, further
studies showed that partial or incomplete reprogramming induced
particular tumor types in vivo (Ohnishi et al., 2014). To elucidate this
time-dependent inﬂuence of OSKM overexpression, the authors used a
doxycycline (dox) inducible system in embryonic stem cells with a
polycystronic cassette encoding either four or three reprogramming
factors. Upon doxycycline exposure, the chimeric mice exhibited time-
dependent dysplasia and tumor formation in various tissue types.
In the kidney, OSKM-induced tumors bear features of a Wilms
tumor, a common pediatric cancer. Interestingly, these tumors only
display epigenetic alterations, as indicated by global changes in their
DNA methylation patterns. Tumors originating from only partially
reprogrammed iPSCs are readily reprogrammed into pluripotent
cells by OSKM expression, thus suggesting a closer relationship to
pluripotency than to the original somatic cell. Another study demon-
strated, a short (b7 d) OSKMoverexpression to lead to teratoma forma-
tion in the kidney and dysplasia in all tissue types, whereas prolonged
overexpression resulted in irreversible tumor formation (Fig. 1). Inter-
estingly, reprogramming of OSKM-induced tumors resulted in non-
tumorigenic iPSCs that contributed to regular organ formation upon
subsequent differentiation in vivo. This indicates that reprogramming
with the Yamanaka factors primarily leads to epigenetic alterations,
generating a “cancer-poised” but not yet “cancer-committed” state
(Ohnishi et al., 2014). Furthermore, the authors addressed distinct
roles of different pluripotency factors during tumorigenesis: while
reprogramming with four (OSKM) or three factors (OKS) led to persis-
tent dysplasia, the exclusion of OCT4 (KMS) initiated reversible dyspla-
sia after removal of doxycycline . This observation is well in line with
previous data, showing that ectopic expression of OCT4 blocksprogenitor differentiation and subsequent dysplasia (characterized by
an expansion of progenitor cells and increased transcriptional activity
of β-catenin) in epithelial tissues (Ohnishi et al., 2014; Hochedlinger
et al., 2005).1.3. Unique properties of cancer stem cells
Similar to normal tissues, cancers comprise heterogeneous cell pop-
ulations with distinct phenotypes, functions, and gene expression pro-
ﬁles (Marte, 2013). The phenotypic characteristics of some cancer
cells, particularly of poorly differentiated to undifferentiated tumors,
have been found to be quite similar to undifferentiated embryonic
cells (Curry et al., 2015; Arsic et al., 2015; Cusulin et al., 2015; Tang
et al., 2015).
Cancer stem cells (CSCs), one of the subgroups of tumor cells, share
some of the critical propertieswith embryonic stem cells such as unlim-
ited self-renewal, multi-lineage differentiation potential, and mainte-
nance of the stemness state. Therefore, the impact of pluripotency
factors, like OCT4, SOX2, KLF4 and c-MYC, in tumorigenesis seems
obvious.
However, the key property of CSCs is their (virtually) exclusive tu-
morigenicity in secondary recipients in vivo. Along these lines, a sub-
population of migratory CSCs has been shown to be exclusively
responsible for metastatic activity of pancreatic cancers (Hermann
et al., 2007). Moreover, CSCs have been demonstrated to drive
chemoresistance and subsequent tumor relapse (Cusulin et al., 2015;
Tang et al., 2015; Saigusa et al., 2009; Todaro et al., 2007; Dean et al.,
2005; Morrison et al., 2011).
In gastrointestinal cancers we and others have demonstrated that
CSCs show elevated expression levels of genes associatedwith stemness
and pluripotency, such as OCT4, Nanog, SOX2, and KLF4 (Lonardo et al.,
2011; Sainz et al., 2015; Hermann et al., 2014), as well as increased ac-
tivity of stemness-associated signaling pathways (Mueller et al., 2009;
Hermann et al., 2013).We have been able to demonstrate that CSCs rep-
resent a challenging but very intriguing target for therapy, and that the
combination of CSC-targeted therapies with standard chemotherapeu-
tic treatment results in signiﬁcantly greater response to therapy.
During different stages of malignant progression, several stemness-
associated genes are speciﬁcally regulated in twomousemodels of pan-
creatic cancer: in fully transformed cells expressing an oncogenic K-Ras
mutation, treatment with nicotine results in upregulation of Oct4 and
also of other genes related to stemness in murine pancreas such as
Sox9, Hes1, ALDH1 and Stat3. Intriguingly, the de-differentiation of aci-
nar tissue seems to be a critical step on the way to K-Ras-mediated
transformation (Kopp et al., 2012). The key acinar regulators Gata6
and Mist1 play an essential role in maintaining acinar differentiation
(Martinelli et al., 2013), but they are repressed by activation of the
“OKSM-member” c-MYC, thus paving the way for malignant transfor-
mation by oncogenic Ras mutations (Hermann et al., 2014).
Patient tumors include a heterogeneous mix of subclones as a result
of branching tumor evolution (Burrell et al., 2013). Multiple genetic and
non-genetic factors drive tumor heterogeneity and contribute to dis-
tinct facets of malignancy: histone modiﬁcation, DNA methylation,
micro RNA and noncoding RNA expression, and genomic mutations as
well as chromosomal aberrations (Meacham and Morrison, 2013). The
mechanism of acquisition and maintenance of CSC properties are not
entirely understood to date. However, their de-regulation of self-
renewal may be a precondition for tumor development (Ricci-Vitiani
et al., 2007; Vermeulen et al., 2008) (Fig. 2).
Further, both the presence as well as the amount of CSCs seem to be
associated with a poor prognosis, respectively (Clevers, 2011). Many of
the genetic alterations in cancer tilt the precise balance between cell dif-
ferentiation and division, favoring the latter, ultimately resulting in a se-
lective growth advantage, due to the fact that differentiating cells
eventually become quiescent or die.
Fig. 1. In vivo overexpression of the four pluripotency factors OCT4, c-MYC, KLF4 and SOX2 (OSKM) leads to epigenetic changes resulting in dysplasia. Extension of OSKM overexpression
subsequently drives tumor formation. Both dysplasia and tumor formation result from an incomplete reprogramming process. Cells derived from these tumors can be fully reprogrammed
towards unaltered iPSCs that do not have tendencies to re-initiate tumorigenesis after blastocyst injection. In case of complete in vivo reprogramming, teratoma formation becomes
apparent. Figure is adapted from Ohnishi et al. (2014).
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formation due to de-differentiation as a result of pluripotency factor
activation. LGR5 is a G-protein coupled receptor marking stem cellFig. 2. Pluripotency factors in cancer development andmaintenance. The four pluripotency facto
in cancer maintenance and achievement of more aggressive properties (metastasis, lymph nodcompartments in tissues with high cell turnover, like in colon, the
small intestine, gastric antral glands, and hair follicles. Genetic silencing
of LGR5 results in reduced proliferation, migration, colony formation,rs (OCT4, c-MYC, KLF4 and SOX2) are sufﬁcient to induce tumorigenesis, play distinct roles
e invasion).
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colorectal cancer). As an example, in gastric cancer the Helicobacter py-
lori associated oncoprotein cytotoxin-associated gene A (CagA) leads to
an aberrant WNT pathway activation, which in turn results in the acti-
vation of WNT target genes, such as CDX1 and LGR5. Subsequently,
markers of de-differentiation like SALL4 andKLF5 are found to be upreg-
ulated (Fujii et al., 2012). In case of gastric cancer, LGR5 overexpression
has great clinical implications, since patients with high levels of LGR5
have a signiﬁcantly poorer outcome as compared to patients with nor-
mal LGR5 levels. Furthermore, LGR5 has been shown to be predictive
for tumor invasiveness and metastasis formation (Fujii et al., 2012).
The generation of CSC-like cells from iPS cells has been described
previously (Lin et al., 2012a). Chen et al. retrovirally transduced several
mouse cancer cell lines with a subset of Yamanaka factors (OKS),
cultured them under non-pluripotency conditions and were able to
demonstrate that these cells showed signiﬁcantly enhanced CSC prop-
erties such as distinct marker gene expression, sphere formation,
chemoresistance, and in vivo tumorigenicity. Interestingly, OKS-
overexpression induced (intestinal) CSC-associated genes like CD133,
CD44, CD26 and LGR5 (Lin et al., 2012a). On the other hand, overexpres-
sion of single factors was not sufﬁcient to induce a complete CSC gene
expression proﬁle. These experiments corroborate the intimate link
between CSCs and the Yamanaka factors as proposed in this review
article.
1.4. Epithelial-mesenchymal transition
The degree of cellular plasticity is illustrated by the ability to under-
go epithelial-mesenchymal transition (EMT)/mesenchymal-epithelial
transition (MET), with both processes being critically important during
embryonic development (EMT type I), tissue regeneration (EMT type
II), and cancer (EMT type III) (Kalluri and Weinberg, 2009;
Unternaehrer et al., 2014; Comes et al., 2013; Shukrun et al., 2014).
The occurring morphogenetic transformation is characterized by the
loss of epithelial properties, like apical-basal polarization or cell–cell ad-
hesion, and simultaneous acquisition of mesenchymal properties, such
as cell motility and degradation of the extracellular matrix (Lamouille
et al., 2014). Particularly in cancer, this cellular phenotype is associated
with increased invasive aswell asmigratory properties. A critical step in
EMT is the downregulation of E-cadherin, which is associated with a
more invasive and undifferentiated phenotype in most gastrointestinal
cancers (Chen et al., 2012a; Jiang et al., 2012; Karayiannakis et al., 1998;
Xu et al., 2014). EMT-type cells and CSCs share molecular characteris-
tics. Moreover the expression switch from E-cadherin to N-cadherin
paves the ground for increased metastatic activity by modifying cell–
cell adhesion as well as the activity of various relevant signaling path-
ways (Christofori, 2006; Yang and Weinberg, 2008; Rathinam et al.,
2011). Notably, EMT has also been linked to chemoresistance in several
cancers (Kalluri and Weinberg, 2009; Yang et al., 2006; Fischer et al.,
2015; Zheng et al., 2015).
However, the contribution of stem cell transcription factors as regu-
lators/drivers in EMT is poorly understood to date. Intriguingly, several
key modulators of pluripotency are closely linked to EMT: A recent
study identiﬁed the SOX17/miR-371-5p/SOX2 axis as an important reg-
ulator of EMT, stemness, and metastasis formation in colorectal cancer,
with miR-371-5p suppressing the EMT-promoting effects of SOX2 (Li
et al., 2015). Co-expression of OCT4 and Nanog initiates both stem cell
characteristics and EMT in hepatocellular carcinoma via activation of
STAT3/Snail signaling (Yin et al., 2015). In contrast to the pro-EMT ef-
fects of OCT4, Nanog and SOX2, there is strong evidence for an opposite
effect of KLF4 via crosstalk with TGF-β, Notch, and WNT signaling (Cui
et al., 2013). Furthermore, Slug, a critical EMT-related transcription fac-
tor, is signiﬁcantly down-regulated in KLF4-expressing hepatocellular
carcinoma cells (HCC) (Lin et al., 2012b). Finally, Tbx3 a pluripotency
factor belonging to the “outer circle” of the pluripotent circuitry
(Dunn et al., 2014), seems to play a triple role: it (i) ﬁne-tunespluripotency and cell fate decisions in embryonic stem cells (Waghray
et al., 2015; Weidgang et al., 2013; Papatsenko et al., 2015), (ii) drives
EMT in colorectal cancer (Shan et al., 2015), and (iii) promotes stemness
in pancreatic CSCs (Ciofﬁ et al., 2015). Altogether, there is accumulating
evidence for a highly relevant overlap between stemness, cancer, and
EMT.
2. OCT4
OCT4 (octamer-binding transcription factor 4), also known as
POU5F1 (POU domain class 5 transcription factor 1) belongs to the fam-
ily of POU-domain transcription factors and is considered to be the key
factor in maintaining and inducing pluripotency (Nichols et al., 1998;
Sterneckert et al., 2012; Esch et al., 2013). Several OCT4 isoforms are dif-
ferentially expressed in human pluripotent and non-pluripotent cells
(Frankenberg et al., 2014). As already mentioned above, Hochedlinger
et al. demonstrated that ectopic expression of OCT4 inhibits cellular dif-
ferentiation, thus leading to dysplasia in epithelial tissues and expan-
sion of progenitor cells (Hochedlinger et al., 2005). Using small
interfering RNA, Hu et al. successfully knocked down the OCT4 gene in
murine and human cancer cell lines, thus inhibiting tumor growth by
decreasing CSC-like populations (Hu et al., 2008). Along with SOX2,
OCT4 stands at the top of a hierarchy governing the regulation of both
pluripotency and de-differentiation andwas found to play an important
role in various gastrointestinal tissues and tumors. OCT4 expression
could be veriﬁed in different esophageal squamous-cell carcinoma
(ESCC) cell lines, whereas cell lines generated from healthy esophageal
tissue remained negative (Wang et al., 2009). Also human ESCC samples
revealed signiﬁcantly increased OCT4 expression levels in poorly differ-
entiated and basaloid subtypes as compared to well-differentiated
counterparts.
Of note, in contrast to healthymucosa, areaswith low-grade dyspla-
sia showed detectable OCT4 expression (Wang et al., 2009; Zhou et al.,
2011). Similarly, OCT4 expression is increased in severe gastritis, meta-
plastic gastric tissue, but most importantly in frank gastric cancer
(Al-Marzoqee et al., 2012; Chen et al., 2009).
Recent publications have suggested an OCT4 activation system,
which is enabled by different transcription factors, such as the zink ﬁn-
ger transcription factor ZIC2. This was demonstrated in human HCC cell
lines, where ZIC2 recruited the nuclear remodeling factor (NURF) com-
plex that subsequently triggered the activation of OCT4 (Zhu et al.,
2015). Interestingly, OCT4 appears to play a dual role in this context:
On the one hand ZIC2 and OCT4 are highly expressed in regenerating
liver tissue (e.g. after partial hepatectomy), contributing to the tremen-
dous regeneration capacity of the liver (Bhave et al., 2011). On the other
hand, OCT4 obviously plays a key role in “somatic reprogramming”
within the process of tumorigenesis. In tumor tissue samples as well
as in human HCC cell lines OCT4 expression levels were elevated com-
pared to the corresponding cirrhotic or normal tissue. The expression
of OCT4 was linked to more de-differentiated HCCs, a higher relapse
rate, and poorer overall survival (OS) (Dong et al., 2012). These results
were conﬁrmed by an independent study, revealing that amore aggres-
sive biological behavior with subsequently worse clinical outcome of
patients was present where tumors expressed both OCT4 and Nanog
(Yin et al., 2012).
In embryonic stem cells OCT4mediates anti-apoptotic properties via
activation of STAT3 signaling, leading to an activation of the anti-
apoptotic protein Survivin. OCT4 does not directly bind within the
Survivin promoter region. Interestingly, the expression of these proteins
is signiﬁcantly increased in chemoresistant tumor stem cells (Wen et al.,
2013). Various other OCT4-dependent mechanisms are thought to be
involved in chemoresistance. In embryonic stem cells, OCT4 inhibits
apoptosis through subsequent TCL1 and AKT activation (Wang et al.,
2010). This mechanism obviously also plays an important role in
tumor-associated chemoresistance and suggests that inhibition of the
AKT pathway might not only reduce cell proliferation, but may also
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OCT4 induces the activation of ABCG2, a membrane transport channel
that functions as an effective multi drug transporting efﬂux pump,
which is able to ship chemotherapeutic agents out of the cells,
thus protecting the cells from harm and thereby contributes to
chemoresistance (Wang et al., 2010).
As indicated above, EMT/MET play a key role in cellular (de-)differ-
entiation. Loss of OCT4 seems to directly contribute to MET induction in
various colorectal cancer lines as shown by knockdown of OCT4: This
resulted in characteristic changes in cell morphology and reduced ex-
pression of EMT marker genes. Most importantly, cell motility, tumor
invasiveness, and hepatic colonization in vivo were signiﬁcantly re-
duced (Dai et al., 2013). In a different study analyzing colorectal cancer
patient tissues, OCT4 expression was signiﬁcantly higher within the
tumors as compared to the adjacent non-cancer tissue. Interestingly,
OCT4 expression levels increased with higher TNM stage and a more
de-differentiated state (Gazouli et al., 2012). In a collective of rectal
cancer patients treated with neoadjuvant radiochemotherapy, the ex-
pression levels of CD133, OCT4, and SOX2 predicted the probability of
distant recurrence and poor prognosis (Saigusa et al., 2009).
During the early stages of pancreatic cancer development OCT4 is
highly expressed, suggesting a role in tumor initiation and early carcino-
genesis: OCT4 expression was signiﬁcantly higher in metaplastic ducts
(79.2% pos. for OCT4) compared to cancer tissue (19.4% pos. for OCT4)
(Wen et al., 2010). Previous reports described a direct correlation be-
tween the expression of OCT4 and the extent of de-differentiation in
pancreatic ductal adenocarcinoma (PDAC), connectingOCT4 expression
to a less differentiated state (Lin et al., 2014). Furthermore, Povlani et al.
displayed increased metastasis to lymph nodes and distant organ sites
in OCT4-positive tumors, resulting in a negative impact on patient
survival (Polvani et al., 2014).
Altogether, OCT4 has been ﬁrmly established as a key player in
various facets ofmalignancy, such as de-differentiation tumor initiation,
invasiveness, metastasis and chemoresistance.
3. SOX2
Similar to OCT4, SOX2 (sex determining region Y-box 2) is involved
in a complex regulatory network of signaling molecules, kinases and
micro-RNAs, ﬁnally inﬂuencing cell (de-)differentiation on a transcrip-
tional, posttranscriptional, and translational level. SOX2, an important
regulator of developmental processes and cell speciﬁcation (Sarkar
and Hochedlinger, 2013), is a crucial factor in the pluripotency network
by maintaining cell pluripotency and promoting self-renewal in ESCs
and iPSCs (Takahashi and Yamanaka, 2006; Brambrink et al., 2008). At
least three different signal transduction pathways are located upstream
of SOX2: FGF-signaling, IL-4/STAT6 signaling and EGFR-SRC-AKT-
signaling (Mansukhani et al., 2005). Further, SOX2 maintains and/or
strengthens various key signaling cascades for tumorigenesis. Upon
SOX2 silencing, expression levels of c-MYC, WNT1, WNT2, and
NOTCH1 in xenografted NOD/SCID mice are attenuated (Chen et al.,
2012b).
Furthermore, SOX2 is functionally active in CSCs, maintaining their
self-renewal capacity (Basu-Roy et al., 2012; Leis et al., 2012). Various
publications characterized the role of SOX2 during oncogenesis and
tumor progression in human colorectal, pancreatic and gastric cancer
(Sanada et al., 2006; Li et al., 2004; Han et al., 2012). Possibly, the
collective link between these observations is the role of SOX2 as a key
regulator of EMT processes, as recently described for colorectal cancer
(Han et al., 2012).
In addition to its fundamental role in themaintenance of embryonic
stem cells, SOX2 is important during embryonic development of gastro-
intestinal organs: SOX2 is expressed in the developing foregut and gas-
tric epithelium. SOX2 co-localizes with p63 in the basal layer of the
esophagus and is critical in the maintenance of the stratiﬁed squamous
epithelium, however it is down-regulated in intestinal metaplasias ofthe stomach and esophagus (Long and Hornick, 2009). In vitro, SOX2
expression promotes cell proliferation in esophageal squamous-cell
carcinoma (Gen et al., 2013). Interestingly, ESCC and esophageal
adenocarcinoma show different expression patterns of SOX2, with
high expression in ESCCs versus low expression in esophageal adeno-
carcinomas (Long and Hornick, 2009). Furthermore, the loss of SOX2
expression correlates well with a dismal overall survival (OS) in adeno-
carcinomas of the esophagus, and serves as an independent prognostic
factor for progression-free patient survival (PFS) (HR 1.91) (Honing
et al., 2014). Altogether, SOX2 seems to play distinct roles in various
tumor types arising from the same organ, which is most likely due to
differences in the genetic regulation of squamous epithelium as com-
pared to glandular epithelium. In line, a multivariate analysis revealed
SOX2 expression as independent prognostic factor for poor overall sur-
vival in gastric cancer patients: SOX2-positive tumors were character-
ized by a more aggressive biological behavior with increased invasion
depth, lymphatic invasion, and lymph node metastasis (Matsuoka
et al., 2012; Otsubo et al., 2008). Considering the WHO classiﬁcation
of gastric cancers, with respect to the histological subtypes of gastric
and intestinal type, the expression of SOX2 is signiﬁcantly higher in
the gastric subtype (Li et al., 2004).
Interestingly, in HCC cell lines the overexpression of SOX2 correlated
with an increased cell invasion and sphere formation ability (Sun et al.,
2013), suggesting a connection to an EMT and CSC phenotype. In HCC
patients, SOX2 expression predicted poor overall survival and prognosis
even after hepatectomy (Sun et al., 2013; Yin et al., 2013). Investigating
SOX2 expression levels in colorectal cancer (CRC) patients, Lundberg
et al. detected expression in 11% of patients (n = 441 CRC tissue sam-
ples) (Lundberg et al., 2014), and demonstrated that the expression
level correlated with liver and lymph-node metastasis and predicts
poor patient survival (Saiki et al., 2009; Lundberg et al., 2014). Further-
more, they discovered an association with BRAFV600E mutations
(Lundberg et al., 2014),whichwas linked to poor prognosis. Interestingly,
no correlation was found regarding KRAS mutations (codon 12 and 13).
SOX2 is not expressed in normal pancreatic acinar or ductal cells of
the pancreas, but was detected in 19.3% out of 217 human PDAC sam-
ples. As in colorectal cancer, the overexpression of SOX2 resulted in en-
hanced cell proliferation, de-differentiation, and an EMT phenotype
(Herreros-Villanueva et al., 2013.) Interestingly, SOX2 levels increased
during PanIN (pancreatic intraepithelial neoplasia) progression, sug-
gesting a role of SOX2 during early pancreatic tumorigenesis. SOX2 ex-
pression is also common (57.1%) in invasive and poorly differentiated
PDACs, corroborating an important role of SOX2 also in themaintenance
of carcinogenesis (Sanada et al., 2006).
4. KLF4
Krüppel-like-factor 4 (KLF4) is a zinc ﬁnger type transcription factor
known to be highly expressed in various human tissues, including epi-
thelial cells of the gastrointestinal-tract (Chen et al., 2003). KLF4 is
able to bi-directionally regulate genes that are controlling cell cycle reg-
ulation, epithelial differentiation, EMT, and apoptosis. On the one hand,
KLF4 is able to induce a p21-dependent cell cycle arrest, thus acting as
a tumor suppressor, whereas on the other hand, in the presence of
pro-oncogenic signals, such as oncogenic RAS, KLF4 is able to inhibit ap-
optosis by inhibition of the Bax/p53-tumorsupressor complex. These
two antithetic effects might explain the apparently divergent roles of
KLF4 in different tumor types, depending on the presence of additional
oncogenic factors.
In the intestine epithelial KLF4 exerts an important role in epithelial
proliferation and differentiation. Here, KLF4 displays an identical ex-
pression pattern as the negative regulator of WNT, APC (adenomatous
polyposis gene) (Chen et al., 2003; Jenkins et al., 1998; Katz et al.,
2005). However, there is further evidence of KLF4 as a driver of carcino-
genesis in gastrointestinal-cancers: thus, as a tumor suppressor, the bi-
ological role of KLF4 is very distinct from SOX2 and OCT4. KLF4 is
354 M. Müller et al. / Stem Cell Research 16 (2016) 349–357commonly decreased or lost in gastrointestinal cancers (Yang et al.,
2005; Wei et al., 2005; Zhang et al., 2012a; Zhang et al., 2012b; Choi
et al., 2006; Patel et al., 2010; Li et al., 2012), and the loss of KLF4 expres-
sion is associated with poor clinical outcome (Wei et al., 2006). KLF4 is
known to be down-regulated during tumor initiation, and consecutively
lost during tumor progression.
In order to determine the expression level of KLF4 aswell as its prog-
nostic relevance, Ma et al. examined 98 ESCC patient samples. KLF4 ex-
pression was signiﬁcantly higher in corresponding normal esophageal
tissue (82.7% positive) as compared to tumor tissue (43.8% positive),
and correlated with the differentiation grade of the tumor. Overall sur-
vival was signiﬁcantly better in the KLF4 expression group as compared
to the KLF4 negative group (median OS of 55 vs. 26 months; 5-year OS
48.8% vs. 25.5%) (Ma et al., 2014). Concerning gastric cancer, clinico-
pathological examination of patient samples revealed a signiﬁcantly
higher overall survival rate in patients with high cytoplasmic KLF4 ex-
pression as compared to low expression (Hsu et al., 2013). A genetically
engineered KLF4 knockout mouse model led to increased stomach cell
proliferation and triggered the formation of precancerous lesions
(Katz et al., 2005). In gastric cancer a frequent abnormal activation of
β-cateninwas linked to increased tumor growth, invasion, andmetasta-
sis (Conacci-Sorrell et al., 2003). In human gastric cancer cell lines KLF4
inhibited β-catenin expression, thus regulating β-catenin-mediated
functions in gastric cancer cells (Zhang et al., 2012b).
Recent publications provide inconsistent results whether the over-
expression of KLF4 is consistently accompanied with a more favorable
outcome in all gastrointestinal cancer types. In HCC the expression pat-
tern of KLF4 is signiﬁcantly increased compared to corresponding adja-
cent non-tumor samples. Correlated to clinicopathological features, the
expression of KLF4 is associatedwith poor tumor differentiation, amore
angio-invasive behavior, and consequently a generally reduced OS (HR
8.61) (Yin et al., 2013). Conﬂictive data has been published by Hsu et al.,
emphasizing the role of KLF4 as a tumor suppressor (Hsu et al., 2013). In
this study, KLF4 expressionwas signiﬁcantly associatedwith amore dif-
ferentiated tumor and a trend towards higher OS, which did not reach
statistical signiﬁcance. In linewith these data, Li et al. (Li et al., 2012) de-
scribed a reduced intratumoral KLF4 expression in HCC samples as com-
pared to normal tissue. These partially antithetical results regarding the
role of KLF4 in tumor formation and its relevance for tumor-associated
mortality, illustrated the need for further investigation and clariﬁcation.
To put the results above into a clinicopathological context, Xu et al.
assessed the KLF4 expression in human samples representative
of colon cancer development: healthy mucosa, sporadic adenoma
and colon cancer. Interestingly, they discovered a dynamic stage-
dependent down-regulation from normal mucosa through adenoma
to cancer, well in line with previously published data (Patel et al.,
2010). Survival analysis revealed a trend towards better survival for pa-
tients with KLF4-positive colon cancers as compared to KLF4-negative
cancers (Xu et al., 2008).
Altogether, the loss of KLF4 has been established as an independent
predictor for survival and recurrence in colon cancer patients (Patel
et al., 2010; Lee et al., 2014). The overexpression of KLF4 in human
PDAC cell lines induced a signiﬁcantly decreased proliferation rate
(Wei et al., 2008), whereas a high number revealed a loss of KLF4 pro-
tein expression (86.8% out of 38 samples). Furthermore, a loss of KLF4
has already been veriﬁed in PDAC precursor lesions (Zammarchi et al.,
2011). Using a KLF4 inducible system in colon cancer cell lines, it has
been demonstrated that the overexpression of KLF4 results in reduced
colony formation, cell migration, and invasion (Dang et al., 2003).
Interestingly, the expression of KLF4α, a splice variant of KLF4, was
associated with reduced survival times in patients (Wei et al., 2010).
5. C-MYC
C-MYC is a well-known transcription factor driving a whole gene
network that is critically involved in the regulation of cell growth andproliferation. Thus, c-MYC is a key transcriptional regulator of genes in-
volved in cell cycle regulation, apoptosis, metabolism, protein synthesis,
and ribosome biogenesis (Dang, 2012; Secombe et al., 2004). Further-
more, c-MYC acts as an oncogene and is commonly up-regulated in up
to 50% of all human cancers (Beroukhim et al., 2010), thereby regulating
pro-tumorigenic transcription factors and signaling cascades such
as KRAS/AKT/PTEN. On a side note, the ARF-p53 pathway mediates
c-MYC-dependent apoptosis, and it is well-known that several
cooperating events, like the loss of p53, are needed for the induction
of carcinogenesis (Gabay et al., 2014). Overexpression of c-MYC is criti-
cally important in gastrointestinal cancers like CRC (Smith and Goh,
1996), and has been demonstrated for up to 40% of gastric cancers
(Greenman et al., 2007), with a signiﬁcantly higher expression in intes-
tinal type cancer as compared to diffuse gastric cancer (Croce, 2008).
However, c-MYC overexpression is not solely limited to gastric malig-
nancies but can also be found in benign lesions like chronic atrophic
gastritis and gastric ulcera (Kraft et al., 2007). The Helicobacter pylori
bacterium is commonly found in the stomach (populations at risk up
to 50% positivity), and a well-established risk factor for the develop-
ment of gastric cancer. Interestingly, c-MYC expression can be stimulat-
ed byHelicobacter pylori infections and reversed bymedical eradication
therapy (Kim et al., 2009; Zambon et al., 2005). The activation of c-MYC
is a key step for the oncogenic reprogramming of hepatic cells such as
fully differentiated hepatocytes (Holczbauer et al., 2013). The expres-
sion level of c-MYC correlate with the tumor's differentiation state:
Low levels of c-MYC result in increased proliferation as well as
enhanced CSC properties such as the concomitant activation of further
reprogramming transcription factors, like Nanog or OCT4. Transcrip-
tional proﬁling indicated that tumors with more immature or
stem-like proﬁles were associated with a signiﬁcantly worse prognosis
as compared to well-differentiated tumors (Dalerba et al., 2011;
Merlos-Suarez et al., 2011). In line with these results, high levels of
c-MYC resulted in loss of CSCs features and induced apoptosis (Akita
et al., 2014).
C-MYC was found to act as a driver for the malignant conversion of
precursors lesions into HCC (Kaposi-Novak et al., 2009). In fact, HCC,
and c-MYC may indeed be responsible for the maintenance and pro-
gression of the cancer. This is supported by data of a genetically
engineered mouse model in which the inactivation of c-MYC resulted
in sustained regression of invasive HCC (Shachaf et al., 2004).
C-MYC has been identiﬁed as an oncogene that acts downstream of
WNT, making it a target of β-Catenin/TCF signaling. APC is the most
commonlymutated tumor suppressor gene in CRC and negatively regu-
lates the β-catenin/TCF cascade. Upon loss of APC, c-MYC becomes
deregulated. This explains that deletion of c-MYC is able to fully abro-
gate the phenotype of APC loss within intestinal epithelial cells. Thus,
an overexpression of c-MYC is commonly seen in human colorectal
adenocarcinomas (Smith and Goh, 1996).
In PDAC c-MYC overexpression signiﬁcantly correlates with worse
overall survival (He et al., 2014) and perineural invasion (He et al.,
2012).
6. Conclusion
There is increasing evidence that the “Yamanaka factors” occupy
key functions in tumorigenesis, regulating key cell functions, such as
cell migration, formation of metastasis, and resistance to therapy. Inter-
estingly, OSKMare quite similarly expressed throughout various gastro-
intestinal cancers, mainly triggering epigenetic changes within the
complex process of tumor formation. However, their speciﬁc roles in
different cancer entities have not been discovered in every detail
so far, particularlywith respect to conﬂicting clinical implications. How-
ever, their presence in various cancers supports the hypothesis
underlining the critical role of CSCs. The functional regulation of
CSCs and the promotion of EMT appear to be closely linked to the
pluripotency status maintained by OSKM and other players of the
355M. Müller et al. / Stem Cell Research 16 (2016) 349–357pluripotency network. This corroborates a great relevance for future
diagnostic and therapeutic approaches by targeting pluripotency factors
and/or CSCs as the supposed root of the tumor.
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